drugset / Trial / NCT00370669

Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

NCT00370669

Phase 3 Unknown 150 enrolled Shahid Beheshti University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)

Timeline

Start
2005-11
Primary completion
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Other
Subject Triamcinolone Acetonide Other / unclassified 2 mg Other